(Q34209528)

English

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study (English)

1 reference

Europe PubMed Central

31 July 2017

1 reference

based on heuristic

inferred from title

John R Teerlink

1

object named as

John R Teerlink

1 reference

Europe PubMed Central

31 July 2017

author name string

Cyril P Clarke

2

1 reference

Europe PubMed Central

31 July 2017

Khalil G Saikali

3

1 reference

Europe PubMed Central

31 July 2017

Jacqueline H Lee

4

1 reference

Europe PubMed Central

31 July 2017

Michael M Chen

5

1 reference

Europe PubMed Central

31 July 2017

Rafael D Escandon

6

1 reference

Europe PubMed Central

31 July 2017

Lyndsey Elliott

7

1 reference

Europe PubMed Central

31 July 2017

Rachel Bee

8

1 reference

Europe PubMed Central

31 July 2017

Mohammad Reza Habibzadeh

9

1 reference

Europe PubMed Central

31 July 2017

Jonathan H Goldman

10

1 reference

Europe PubMed Central

31 July 2017

Nelson B Schiller

11

1 reference

Europe PubMed Central

31 July 2017

Fady I Malik

12

1 reference

Europe PubMed Central

31 July 2017

Andrew A Wolff

13

1 reference

Europe PubMed Central

31 July 2017

language of work or name

0 references

publication date

1 August 2011

1 reference

Europe PubMed Central

31 July 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

31 July 2017

378

1 reference

Europe PubMed Central

31 July 2017

9792

1 reference

Europe PubMed Central

31 July 2017

667-675

1 reference

Europe PubMed Central

31 July 2017

The search for the ideal positive inotropic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Executive Summary: Heart Disease and Stroke Statistics—2010 Update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiac inotropes: current agents and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel approach to improve cardiac performance: cardiac myosin activators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Confidence interval criteria for assessment of dose proportionality.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of cardiac myosin isoform variation on myofilament function and crossbridge kinetics in transgenic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A critical review of the systolic time intervals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Systolic time intervals in heart failure in man

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Performance of phonoelectrocardiographic left ventricular systolic time intervals and B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of left ventricular function by cardiac ultrasound.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961219-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(11)61219-1

1 reference

Europe PubMed Central

31 July 2017

release_h7vgcv3p5ze63eoppigf5shk2i

1 reference

https://api.fatcat.wiki/v0/release/h7vgcv3p5ze63eoppigf5shk2i

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34209528&oldid=1843934627"